| pubmed-article:1847733 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1847733 | lifeskim:mentions | umls-concept:C0037135 | lld:lifeskim |
| pubmed-article:1847733 | lifeskim:mentions | umls-concept:C0014792 | lld:lifeskim |
| pubmed-article:1847733 | lifeskim:mentions | umls-concept:C0023890 | lld:lifeskim |
| pubmed-article:1847733 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:1847733 | lifeskim:mentions | umls-concept:C0243067 | lld:lifeskim |
| pubmed-article:1847733 | lifeskim:mentions | umls-concept:C0332162 | lld:lifeskim |
| pubmed-article:1847733 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:1847733 | pubmed:dateCreated | 1991-4-2 | lld:pubmed |
| pubmed-article:1847733 | pubmed:abstractText | The time-course of some alterations produced in erythrocytes during the onset of CCl4-induced liver cirrhosis was studied in rats. Erythrocyte membranes were isolated to measure Na+, K+ and Ca+2-ATPase activities. Membrane lipid composition was determined to calculate the cholesterol/phospholipid ratio and serum samples were used to measure lipoperoxidation. The results demonstrated that as CCl4 treatment progressed, serum lipoperoxidation and membrane cholesterol/phospholipid ratio increased while ATPase activities decreased. ATPase activities in red blood cells of cirrhotic rats were 50% below normal values but those determined in cells of animals treated simultaneously with CCl4 + silymarin were significantly improved. Silymarin co-treatment also preserved the normal cholesterol/phospholipid ratio in the membranes. Our results suggest that the measure of ATPase activities in erythrocytes membranes could be a simple, safe and useful early marker of liver damage and also valuable to test the effectiveness of a given drug therapy. | lld:pubmed |
| pubmed-article:1847733 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1847733 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1847733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847733 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1847733 | pubmed:issn | 0024-3205 | lld:pubmed |
| pubmed-article:1847733 | pubmed:author | pubmed-author:MourelleMM | lld:pubmed |
| pubmed-article:1847733 | pubmed:author | pubmed-author:FrancoM TMT | lld:pubmed |
| pubmed-article:1847733 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1847733 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:1847733 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1847733 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1847733 | pubmed:pagination | 1083-90 | lld:pubmed |
| pubmed-article:1847733 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:meshHeading | pubmed-meshheading:1847733-... | lld:pubmed |
| pubmed-article:1847733 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1847733 | pubmed:articleTitle | Erythrocyte defects precede the onset of CCl4-induced liver cirrhosis. Protection by silymarin. | lld:pubmed |
| pubmed-article:1847733 | pubmed:affiliation | Departamento de Farmacología y Toxicología, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, México D.F. | lld:pubmed |
| pubmed-article:1847733 | pubmed:publicationType | Journal Article | lld:pubmed |
